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Characterisation of the Carboxypeptidase G2 Catalytic Site and 
Design of New Inhibitors for Cancer Therapy 
Dhadchayini Jeyaharan,[a] Carla Brackstone,[a] James Schouten,[b] Paul Davis,[b] and Ann M. Dixon*[a] 
Abstract: The enzyme carboxypeptidase G2 (CPG2) is utilized in 
antibody directed enzyme pro-drug therapy (ADEPT) to catalyze the 
formation of an active drug from an inert pro-drug. Free CPG2 in the 
bloodstream must be inhibited before administration of the pro-drug 
in order to avoid a systemic reaction in the patient. Although a few 
small-molecule CPG2 inhibitors have been reported, none have been 
taken forward thus far. This lack of progress is due in part to a lack of 
structural understanding of the CPG2 active site as well as the 
absence of small molecules that can block the active site whilst 
targeting the complex for clearance. The work described here aimed 
to address both areas. We report the structural/functional impact of 
extensive point mutation across the putative CPG2 catalytic site and 
adjacent regions for the first time, revealing residues outside the 
catalytic region (K208A, S210A and T357A) crucial to enzyme activity. 
We also describe novel molecules that inhibit CPG2 whilst 
maintaining accessibility of galactosylated moieties aimed at targeting 
the enzyme for clearance. This work acts as a platform for future 
development of high-affinity CPG2 inhibitors that occupy new 
chemical space and will advance the safe application of ADEPT in 
cancer treatment. 
 
Introduction 
 The enzyme carboxypeptidase G2 (CPG2) is a member of 
the aminoacylase-1 / metallopeptidase 20 (Acy1/M20) family and 
is considered to be a very promising therapeutic agent in 
anticancer treatment, specifically in antibody directed enzyme 
pro-drug therapy (ADEPT)[1]. The concept of ADEPT was put 
forward in the mid-1980s as a method of restricting the effects of 
cytotoxic drugs to the site of tumors [1] in an effort to circumvent 
the adverse impact on healthy tissues observed in treatments 
such as chemotherapy. In order to exclusively produce and retain 
a cytotoxic drug at tumor sites, the ADEPT approach utilizes 
CPG2 to catalyze the degradation of an inert pro-drug into an 
active drug molecule at the site of a tumor.  This can be 
conceptualized in three stages, as shown in Figure 1A.  In the first 
stage of ADEPT, CPG2 is administered as an immunoconjugate 
attached to an antibody directed at a tumor-associated antigen. 
Binding of this antibody to its antigen localizes CPG2 to the tumor, 
where it is readily available to enzymatically activate a pro-drug 
(see Figure 1A, Stage 3) [2].  CPG2 was first described as a folate 
hydrolyzing enzyme, with a preference for folic acid and its 
analogues, such as methotrexate (MTX) (Figure 1B), displaying 
an L-glutamate in the carboxy-terminal position [3]. CPG2 
mediates the release of the C-terminal glutamate residue in both 
folic acid and MTX, and has been employed in ADEPT to activate 
glutamated nitrogen mustard pro-drugs such as ZD2767P (Figure 
1B) [4].   
 Pre-clinical experiments concluded that, between stages 1 
and 3, an intermediate step was required involving the inhibition 
and clearance of unbound CPG2 immunoconjugate from the 
circulatory system (Figure 1A, Stage 2) [5]. Failure to clear free 
CPG2 resulted in systemic toxicity, therefore development of 
CPG2 inhibitors and clearance agents is required for further 
development of ADEPT as a cancer treatment. One strategy that 
has been developed to overcome this is the use of a 
galactosylated antibody selective for the enzyme portion of the 
immunoconjugate and designed to enhance clearance of the free 
immunoconjugate through the liver [6]. Galactosylation was 
selected in order to facilitate rapid uptake by receptors in the liver, 
minimizing circulatory dwell time, and was shown to reduce CPG2 
concentration in the blood without significantly reducing the 
concentration of enzyme at tumor sites [7-9].  Khan and coworkers 
took another approach, exploring the use of small molecule 
inhibitors of CPG2 to inactivate free enzyme in circulation.  These 
were designed to contain the common structural features found in 
known substrates, such as an α-carboxylate moiety on the 
glutamate residue and a benzene ring close to the carbonyl 
carbon of the amide bond [10, 11]. They also included a 
thiocarbamate moiety attached to a benzene ring (Figure 1B), and 
while these inhibitors were potent, they were non-competitive 
towards MTX and have not been reported in applications of 
ADEPT to date.     
 Characterization of the active site structure and critical 
protein-ligand interactions has significant implications in 
advancing the design of new tumor pro-drugs and CPG2 inhibitors. 
The crystal structure of un-liganded CPG2 was solved in 1997 
(PDB ID 1CG2, shown in Figure 1C) [12], and demonstrated that 
the enzyme is organized into a discontinuous catalytic domain 
(residues 23–213 and 326–415) which contains a dinuclear Zn2+-
binding site composed of five residues (see Figure 1D).  The 
residues that comprise the CPG2 Zn-binding site are well 
conserved with other metallopeptidases of known structure, as 
shown in the multiple sequence alignment of representative 
proteins of known structure in Figure S1 [12-17]. The dimerization 
domain, responsible for stabilizing homodimer formation, is 
inserted into the center of the catalytic domain (residues 214–325). 
This architecture is also shared with other members of the Acy1 / 
M20 family including human aminoacylase-1 [18], but further 
attempts at co-crystallization of CPG2 with ligands, substrates or 
inhibitors have not been reported.  This has led to very little  
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Figure 1. (A) Schematic describing the various stages of antibody-directed 
enzyme pro-drug therapy (ADEPT). In Stage 1, an antibody-enzyme conjugate 
(Ab-CPG2) is directed at a tumour-associated antigen and retained at the tumor 
site. Stage 2 involves administration of a glycoslated enzyme 
inactivating/clearing agent, which inhibits the enzyme and rapidly removes 
excess immunoconjugate from the blood via hepatic receptors. Stage 3 
describes administration of a non-toxic pro-drug leading to localised generation 
of a potent cytotoxic agent (e.g. benzoic acid mustards) at tumor sites via CPG2-
mediated cleavage of the protective moiety from the pro-drug3. (B) Chemical 
structure of CPG2 substrates (methotrexate and folic acid) and previously 
known CPG2 inhibitors (Khan’s inhibitor and ZD2767P). Highlighted in red is the 
D-amino acid glutamate. (C) The different residues within CPG2 proposed to 
make up the substrate binding-site mapped onto the crystal structure (PDB ID 
1CG2). (D) Close-up of the region possibly involved in MTX hydrolysis. In pink 
are shown residues involved in catalysis, in red residues possibly interacting 
with the pteridine moiety of MTX (S1 pocket) and in yellow the residues that may 
be in contact with the glutamate group of MTX (S1’ pocket). 
progress over the past 20 years in establishing key features of 
CPG2 such as the location of its substrate-binding site and the 
presence of additional ligand-binding sites. 
Thus far, our current working understanding of the 
molecular basis of CPG2 activity is largely based on sequence / 
structural homology to other metallopeptidases and molecular 
modelling. Specifically, molecular docking and molecular 
dynamics (MD) simulation was used in 2012 to investigate in silico 
the possible modes of substrate (specifically MTX) binding to the 
CPG2 crystal structure [19]. The results from this study suggested 
that MTX interacts with Glu, His and Asp residues in the putative 
catalytic domain (shown in pink in Figure 1D).  These residues 
are also involved in Zn2+ coordination, and are thus well-
conserved throughout the Acy1/M20 family (see Figure S1).  
Molecular docking also indicated that residues in an adjacent 
pocket (Pocket S1, shown in red in Figure 1D) could 
accommodate the N-terminal pteroate moiety of MTX via putative 
hydrogen bonds between nitrogen atoms in pteridine and the 
carboxyl oxygens from S210, K208 and T357. The glutamate side 
chain of MTX was localized in a separate region adjacent to the 
catalytic site (Pocket S1’, shown in yellow in Fig. 1D) and models 
suggested hydrogen bonding between the glutamate and 
residues R324 and G360 in the enzyme. Rowsell et al. showed 
that substitution of R324 to alanine resulted in a mutant CPG2 
with very low activity towards MTX [12], confirming that the S1’ 
pocket participates in substrate binding / recognition.  Surprisingly, 
this is the only residue in the proposed MTX binding region that 
has been studied experimentally via site-directed mutagenesis in 
vivo or in vitro (although Yachnin and coworkers recently reported 
creation of CPG2 permutants at sites adjacent to this region [20]).  
The residues in the putative S1 and S1’ pockets appear to be 
poorly conserved in our sequence alignments of other family 
members, as shown in Figure S1. 
 Despite the scarcity of data for CPG2, investigation of 
homologs including human Acy1 [21] and mouse carnosinase 2 
(mCN2) [13] has yielded a model for enzyme function in which 
substrate binding leads from an “open” conformation to a “closed 
lid” conformation.  This structural rearrangement is required for 
catalytic activity in several cases, and involves residues in both 
the catalytic and dimerization domains with key residues in the 
dimerization domain having been identified [21].  However, we 
have recently demonstrated that the catalytic domain of CPG2 
retains activity against MTX even after deletion of the entire 
dimerization domain [22]. This result, coupled with the lack of 
conservation of residues in the S1 and S1’ pockets suggests that 
CPG2 may possess unique substrate-binding characteristics 
worthy of exploration.   To advance our understanding of CPG2 
substrate and inhibitor binding, we report for the first time the 
impact of extensive point mutation across the catalytic site and 
putative S1 binding pocket on protein folding, thermal stability, 
and enzyme activity against MTX.  This work acts as the first 
robust test of current, in silico models that have represented the 
state-of-the-art up to this time.  We also report development and 
production of novel molecules that can inhibit the CPG2 catalytic 
site whilst maintaining the accessibility of galactosylated moieties 
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aimed at directing the molecules for clearance. Saturation transfer 
difference NMR spectroscopy (STD-NMR) was used to measure 
the binding affinities of all three inhibitors to CPG2, as well as 
identify the binding epitopes within each inhibitor.  This work acts 
as a platform for future development of high-affinity CPG2 
inhibitors that occupy new chemical space and will advance the 
safe application of ADEPT in cancer treatment.   
Results and Discussion 
Mutagenesis strategy and production of wild-type CPG2 and 
targeted mutants 
 Thus far, molecular docking of MTX to CPG2 has given us 
our best indication of which residues line the substrate binding 
site, and adjacent hydrophilic and hydrophobic pockets that may 
direct substrate recognition and cleavage (see Figure 1D).  Of the 
11 residues highlighted in this previous work, only one residue 
(R324) has been mutated to demonstrate a reduction in CPG2 
activity towards MTX. We recently published results 
demonstrating high-yield soluble expression, purification and 
activity of CPG2 lacking the N-terminal signal peptide (CPG223-
415) [22]. To test the role of residues within and adjacent to the 
catalytic site in CPG2 activity, we prepared eight point mutants of 
the Hisx6-CPG223-415 enzyme in which H112, H385, E175, E200, 
D141, K208, S210, and T357 were substituted for Ala using site-
directed mutagenesis.  
 
 The eight resulting proteins were expressed and purified as 
described previously [22], and the relative expression levels are 
shown in Figure 2. All eight proteins displayed slow migration in 
SDS-PAGE, reflecting a molecular weight (~52 kDa) roughly 14% 
higher than the theoretical mass (45.5 kDa). This anomalous 
migration has been suggested in the past for extended proteins, 
acidic proteins [23], and cytosolic proteins that contain surfactant-
binding regions [24].  CPG2 is not acidic nor significantly extended, 
but may contain regions that, when unfolded on the gel, can 
interact with surfactant molecules slowing migration. Regardless, 
identity of all proteins was confirmed in later experiments. The 
H112A mutant had the lowest expression level, followed by 
K208A and S210A mutants, while the lowest level of expression 
and the H385A mutant displayed the highest level of expression. 
The protein yields (per liter of culture) after purification were 
determined using the BCA assay, and are summarized in Table 
1.  All substitutions lead to a decrease in expression level 
(compared to wild type).  Sample purity and identity of all purified 
proteins were confirmed SDS-PAGE gel analyses (Figure S2). 
Sample purity and identity were also confirmed using mass 
spectrometry, and Table 2 summarizes the theoretical versus 
observed masses of wild-type CPG223-415 (referred to from this 
point forward as simply CPG2) and all eight mutant proteins. All 
proteins were identified at the exact predicted molecular mass ±1 
Dalton, except for E175A, which was observed at −1.9 Da from 
the predicted mass. The Hisx6 tag was then removed from all 
proteins via proteolytic cleavage at a TEV cleavage site followed 
by further purification as detailed in the Methods. 
Figure 2. Coomassie-stained SDS-PAGE gel comparing expression levels of 
wild-type CPG2 and point mutants. Recombinant mutant proteins were tested 
for expression before (U) and after (I) induction with 0.5 mM IPTG. The dense 
band migrating just below the 58 kDa marker, which appeared after induction in 
the majority of cases, was shown to contain the protein of interest.  Leaky 
expression was observed in samples containing the K208A and S210A 
substitutions, where protein can be seen both pre- and post-induction. 
Table 1. Expression yield, enzymatic activity assays and melting 
temperatures of wild-type CPG2 and eight mutant proteins. 
Constructs Expression yield 
(mg/L) 
Specific Activity 
(U/mg) 
Melting 
temperature, 
Tm (°C) 
CPG223-415 251.6 96.7 60.4 
H112A mutant 23.4 3.9 28.2 
H385A mutant 153.1 50.9 55.1 
E175A mutant 
E200A mutant 
D141A mutant 
K208A mutant 
S210A mutant 
T357A mutant 
74.9 
125.8 
151.0 
63.1 
114.8 
112.1 
2.4 
63.7 
1.8 
3.9 
1.5 
1.4 
71.4 
64.3 
53.2 
53.4 
54.4 
55.4 
 
 
Table 2. Mass average of all expressed constructs, containing N-
terminal His6 tag and TEV cleavage site, obtained from LC-ESI UHR 
QTOF mass spectrometry. 
 
Constructs 
 
Theoretical 
Mass (Da) 
 
Observed 
Mass (Da) 
 
 
Mass Shift 
(Da) 
CPG223-415 45478.6 45477.9 -0.7 
H112A mutant 45412.6 45411.7 -0.9 
H385A mutant 45412.6 45411.8 -0.8 
E175A mutant 
E200A mutant 
D141A mutant 
K208A mutant 
S210A mutant 
T357A mutant 
45420.6 
45420.6 
45434.6 
45421.5 
45462.6 
45448.6 
45418.7 
45418.7 
45433.7 
45420.8 
45461.8 
45447.7 
-1.9 
-0.9 
-0.9 
-0.7 
-0.8 
-0.9 
 
 
Impact of active-site amino acid substitutions on protein fold, 
thermal stability and activity 
 The impact of the eight different point mutations on the 
global protein fold was assessed using circular dichroism (CD) 
spectrophotometry. As shown in Figure 3A, far-UV CD spectra of 
the proteins at 25°C have similar shape and intensity, with a 
negative CD band at 209 nm and positive band at approximately 
190 nm. The CD data at 25°C were fitted using the CDSSTR 
FULL PAPER    
For internal use, please do not delete. Submitted_Manuscript 
 
 
 
 
algorithm in DichroWeb [25], and the percentage secondary 
structure content was estimated for each protein as shown in 
Figure 3B. The data indicated that all of the mutated proteins 
contain very similar secondary structure content to that observed 
in the wild-type protein.  
Figure 3. (A) Circular dichroism spectra collected between 190-240 nm for wild 
type CPG2 and all mutants. (B) Percentage of secondary structure for wild-type 
CPG2 and all mutants using DichroWeb.[12] 
 While the global secondary structure was unaffected by the 
active-site and adjacent substitutions made, the thermal stability 
of the proteins did show variation (Table 1 and Figure S3).  
Thermal stability was determined by plotting loss of protein 
secondary structure (monitored by CD signal at 220 nm) as a 
function of temperature. All proteins studied here precipitated 
after they were melted at 90°C, indicating that irreversible 
unfolding is likely.  
 The presence of a sigmoidal curve is widely considered a 
strong indication of the occurrence of a two-state denaturation 
process [26], where only the folded and unfolded states are 
reasonably populated at equilibrium [27, 28]. Wild type CPG2 is a 
non-globular, large multi-domain protein that tends not to exhibit 
distinct phase transitions during thermal unfolding and, as 
expected, yielded a sigmoidal relationship suggesting a 2-state 
transition during thermal denaturation (Figure S3). Fitting of this 
curve yielded a melting temperature (Tm) of 60.4°C. Proteins 
containing the H385A, E200A, D141A, K208A, S210A and T357A 
substitutions also yielded data that fitted well to a sigmoidal curve, 
and melting temperatures close to that of the wild-type protein 
(53.2 − 64.3°C). The H112A substitution yielded the lowest Tm 
value of 28.2°C, suggesting that removal of H112 significantly 
decreases stability of the protein fold. This result may explain the 
very low yield of this protein (Figure 2). Conversely, the E175A 
substitution increased the Tm to 71.4°C, implying that removal of 
E175 increases stability of the protein. 
 The catalytic activities of all proteins were estimated by 
monitoring the rate of degradation of MTX spectrophotometrically 
at 320 nm (Figure S4A) as described in the Methods. The results, 
summarized in Table 1, suggest no obvious correlation between 
thermal stability and activity, therefore differences in activities 
were interpreted in terms of MTX-binding in the active (and 
adjacent) site. It was expected that substitutions disturbing the 
putative catalytic site would abolish activity of CPG2, whereas the 
mutations involving the adjacent S1 pocket would result in 
reduced activity of CPG2. This was the case for proteins carrying 
the H112A, E175A and D141A substitutions (predicted to lie in the 
catalytic site and coordinate to Zn2+), as all three proteins were 
rendered inactive against MTX (returning activities of 1.8−3.9 
U/mg, values we suggest are insignificant within error and are 
likely due to non-specific background) likely due to removal of key 
protein-Zn2+ and protein-ligand interactions sites and in line with 
homologous mutations made in human Acy1 [18]. H385A and 
E200A (also found in the putative catalytic site) showed specific 
activities of 50.9 and 63.7 U/mg, respectively, approaching that 
observed for the wild-type enzyme (96.7 U/mg). Both of these 
residues are involved with coordination of Zn2+ (Figure 1D), so 
their activity was surprising especially given that the homologous 
mutations in human Acy1 (H373 and E175) were shown to abolish 
enzyme activity [18]. This tolerance for the absence of one of these 
two coordination sites in CPG2 without causing a large loss in 
catalytic activity or a change in secondary structure, alongside the 
known requirement for two Zn2+ ions across this family of 
enzymes, suggests that another coordination site is made 
available upon mutation. Zinc is known to be coordinated by a 
range of protein side chains, including the nitrogen of histidine, 
the oxygen of aspartate or glutamate and the sulfur of cysteine, 
and more rarely to ligands including the hydroxyl of tyrosine [29]. 
In the case of E200A, inspection of the CPG2 crystal structure [12] 
reveals that Asp142 is close by in the active site, and upon 
mutation of E200 to Ala, may be able to rearrange and take up 
the role of a Zn2+ coordination site. In the case of the H385A 
mutant, the neighboring Tyr384 also in the loop region may 
coordinate Zn2+ to rescue activity.  Alternatively, the remaining 
four residues may coordinate Zn2+ in an altered manner, such as 
the bidentate coordination via both carboxylate oxygens in 
Glu200 and Glu176.    
 Substitutions in the adjacent S1 pocket, namely K208A, 
S210A and T357A, also abolished CPG2 activity (1.4−3.9 U/mg, 
see Table 1). This almost complete reduction in activity indicates 
beyond doubt the importance of these adjacent residues in 
enzyme function, possibly playing a role in substrate recognition.  
As mentioned earlier, there is little apparent conservation of 
sequence in the S1 pocket, making broader comparison with 
other family members difficult.  Unno and coworkers reported that 
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substitution of His228, a residue that resides in the S1 pocket of 
mouse carnosinase CN2, with Ala also impacted substrate 
recognition [13]. Okumura and coworkers also reported that H228 
was essential to enzymatic reaction [30].  In CN2, the residues in 
the S1 pocket are quite different to those in CPG2, so it would 
appear that there is a good deal of sequence diversity in these 
adjacent regions. Our results, therefore, are the first of their kind 
in experimentally defining the residues that direct CPG2 catalytic 
activity, and revealing the unique nature of substrate recognition 
in this enzyme. 
 
Design, Preparation and Inhibition of Next Generation CPG2 
Inhibitors  
 
Antibody directed enzyme pro-drug therapy has been 
hampered by off-site activation of the pro-drug by circulating 
protein-enzyme conjugates in normal tissues. The development 
of a CPG2 inhibitor/clearing agent would facilitate efficient 
clearance of CPG2 from the bloodstream prior to pro-drug 
administration, thus eliminating any off-site activation. The ideal 
agent would contain one component that binds with high affinity 
to the active site of the CPG2 enzyme, thus blocking activity, and 
a second component that directs the inactive antibody-enzyme 
conjugate to the liver for clearance.  
 
Three candidate inhibitors for CPG2 were designed as 
shown in Figure 4 and synthesized as described in the Methods. 
These inhibitors all contained the key glutamate residue at the 
carboxy terminus that directs binding of all known CPG2 
substrates and past inhibitors (Figure 1B). Molecular docking 
results indicated that the Glu side-chain in MTX is stabilized via 
hydrogen bonding to Arg324 in the S1’ pocket, while the amide 
hydrogen interacts with a carboxyl group on Glu175 in the 
catalytic site [19].  Our mutagenesis data shows abolishment of 
activity upon mutation of E175, supporting critical interactions 
between the Glu moiety and this region of the enzyme. However, 
L-glutamate was replaced with D-glutamate in order to prevent 
hydrolysis of the peptide bond whilst retaining binding affinity for 
CPG2. 
 
Our mutagenesis results also clearly implicated residues in 
the S1 pocket as key sites of interaction with the substrate.  
Specifically, substitution of K208, S210 and T357 all abolished 
activity against MTX. This is in good agreement with the molecular 
model proposed by Turra and coworkers in which putative 
hydrogen bonding interactions between the endo and exocyclic 
nitrogen atoms in the pteridine moiety of MTX and the carbonyl 
oxygens of Lys 208 and Ser 210 stabilize binding of this region of 
the molecule. To account for the role of interactions in the S1 
pocket, which our mutagenesis studies confirmed played a role in 
substrate recognition, the molecule termed CP06 contained a 
naphthylamine group which contains an aromatic heterocyclic 
component with a nitrogen substitution.  This substituent was 
linked to the glutamate moiety via a peptide bond.  A second 
inhibitor, CP67 (Figure S5), was prepared by addition of three 
galactose units to the N-terminal naphthylamine group of CP06 
via a tripeptide linker.  This galactosylated tail was added to 
facilitate clearance of the CPG2-inhibitor complex via the liver by 
binding to hepatocyte receptors (i.e. asialoglycoprotein receptors). 
The third inhibitor tested, referred to as CP42, contained the 
carboxy terminal glutamate residue, a hydrophobic moiety 
containing a single aromatic ring (analogous to the Khan inhibitors 
and nitrogen mustard prodrugs shown in Fig. 1B), and a nitrogen-
substituted peptide chain terminating in a single galactose unit 
(Figure 4A).  This inhibitor was designed to test the requirement 
for a heterocyclic ring versus alternative hydrophobic, nitrogen 
bearing structures.  
Figure 4. (A) Chemical structures of CP06, CP67 and CP42, with D-glutamate 
shown in bold. The complete CP67 structure can be found in Figure S4. (B) Plot 
of CPG2 activity, as determined using the methotrexate cleavage assay (see 
Methods), in the presence of increasing concentrations of CP06, CP67 and 
CP42. Data were fitted to an inhibitory dose-response curve in Origin Pro 2015, 
and the half maximal inhibitory concentration (IC50) was obtained from the fit.  
IC50 values of 68 μM and 113 μM were obtained for CP06 and CP67, 
respectively, while CP42 showed no inhibition. 
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 The ability of each of these novel inhibitors to inhibit activity 
of CPG2 was assessed by monitoring the rate of degradation of 
MTX spectrophotometrically at 320 nm.  In order to calculate IC50 
values for each inhibitor, the specific activities were measured 
across a range of inhibitor concentrations as shown in Figure 4B, 
and fitted to a standard dose-response function using OriginPro. 
CP06 inhibited the MTX-degrading activity of CPG2 with an IC50 
of 68 μM, making it the strongest inhibitor of the three prepared 
here. To demonstrate that this molecule was acting as a genuine 
inhibitor as opposed to a slowly hydrolysable substrate, we 
developed a coupled enzyme assay for the detection of glutamic 
acid. The results are shown in Figure S6 and compared to 
equivalent data for the well-known CPG2 substrate folic acid. 
Evolution of glutamate from folic acid is immediately apparent as 
an increase in fluorescence intensity, and continues to increase 
steadily over the duration of the measurement. Conversely, the 
flat line obtained for CP06 suggests that no glutamic acid is 
evolved in the presence of CPG2 and that it is not a substrate but 
a genuine inhibitor.  
 
Galactosylation of CP06, to create CP67, increased the IC50 
by a factor of two (113 μM), suggesting that addition of the 
tripeptide chain and galactosylated tail weakened binding slightly. 
Replacing the hydrophobic naphthylamine group with a larger and 
more complex, but less hydrophobic, moiety as in CP42 
eliminated inhibition of CPG2 and the enzyme was able to turn 
over MTX at its optimal rate.   
STD-NMR Measurement of Binding Epitope and Affinity of 
New Inhibitors 
 Saturation-transfer difference NMR (STD-NMR) was then 
used to determine which groups in CP06 and CP67 make up the 
site of interaction with CPG2, thus facilitating binding and 
inhibition.  In an STD-NMR experiment, selective saturation of a 
protein host can be transferred to protons in a ligand via the 
nuclear Overhauser effect if those protons are within 5 Å of the 
protein [31]. This results in NOE enhancement of the signals from 
“bound” protons within the ligand, which can be detected via 
subtraction of the on-resonance 1H spectrum, acquired upon 
selective irradiation of the protein, from the off-resonance 1H 
spectrum, acquired with no saturation of the protein. Any proton 
signals that remain in this difference spectrum identify which 
protons in the ligand form the binding epitope – this method is 
thus called “epitope mapping” [32]. 
 The CP06, CP67 and CP42 inhibitors yielded well-resolved 
1H 1D NMR spectra at 700 MHz, and these spectra were 
assigned as shown in Figure 5 (CP06 and CP67) and Figure S7 
(CP42). Although some spectral resonances partially overlapped 
(most notably in the polyether linker in CP67 and galactose-
containing regions of both CP67 and CP42), the majority of 
hydrogen atoms were able to be assigned. The saturation transfer 
difference (STD) spectrum for each inhibitor in the presence of 20 
µM CPG2 is shown immediately below each 1H spectrum in 
Figures 5 and S7, and clearly revealed efficient saturation transfer  
Figure 5. Single Inhibitor titration STD NMR experiments of (A) CP06 and (B) 
CP67 binding to CPG2. The top spectrum in each panel corresponds to the 1D 
1H reference spectrum of the inhibitor, and the bottom to the 1D 1H STD NMR 
difference spectrum which reveals inhibitor residues that directly interact with 
CPG2.  Also shown are the structures of the inhibitors tested and the relative 
saturation of the individual protons normalised to that of the H6 proton as 
determined from 1D STD NMR spectra at an 80 fold molar excess of inhibitor. 
Absence of the saturation of a proton is not depicted. The few sharp resonances 
arise from low-molecular-weight are impurities. STD NMR spectra are shown 
for samples containing 1.6 mM inhibitor and 20 μM CPG2, and were recorded 
at 298 K on a 700 MHz spectrometer. 
from CPG2 to a subset of 1Hs in each inhibitor. The signals 
contained in the STD spectra identified the protons in each 
inhibitor that were involved in CPG2 binding – this is one of the 
unique strengths of STD NMR in comparison with other methods 
typically used to measure affinity of binding such as isothermal 
titration calorimetry (ITC) or surface plasmon resonance (SPR). 
The signal intensities of the individual protons in the STD spectra 
were normalized to the integral value of the proton displaying the 
highest STD amplification (which itself was set to 100%), and 
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values > 35% are shown in Figures 5 and S7.  These values were 
then used to reflect the proximity of each inhibitor proton to CPG2. 
The lowest STD effects (< 30%) were observed for the 
galactosylated moieties of CP67 and CP42 as well as the majority 
of the polyether linker protons, suggesting these regions do not 
bind to CPG2 and thus remain accessible for hepatocyte receptor 
binding, as expected. The glutamate protons of CP42 also 
showed no saturation transfer, which was unsurprising given the 
complete lack of inhibitory activity observed for this molecule. The 
data suggest that simultaneous recognition of the carboxy-
terminal glutamate and the hydrophobic phenyl moiety within the 
CPG2 binding site was prevented in this inhibitor, with only the 
hydrophobic phenyl group acquiring any significant saturation in 
CP42 likely explained by transient non-specific binding. However, 
in both CP06 and CP67 high levels of saturation transfer from 
CPG2 are observed in protons across both the glutamate and the 
hydrophobic naphthylamine groups (Figures 5A and B), indicating 
the simultaneous binding of both regions to the enzyme.   
 STD-NMR experiments can also be used to estimate 
binding affinity of each inhibitor by obtaining STD spectra for 
samples with inhibitor:protein molar ratios from 1:1−80:1. The 
STD binding isotherms, in which STD amplification factor (STD-
AF) is plotted against inhibitor concentration, are shown in Figure 
S8 for all 1Hs displaying saturation transfer. The data were fitted 
to Equation 2 to yield an estimate of the apparent dissociation 
constant (KD,app) for the interaction, and these values are 
summarized in Table 3. A range of KD values were obtained for 
the various 1Hs in each ligand, leading to a ~30% standard 
deviation in the average values.  This is one of the shortcomings 
of STD-NMR, and it has been shown that the complex 
dependence of STD intensities on the spectral properties of the 
observed signals make it very challenging to obtain accurate 
affinities directly using this method [33]. In the case of CP06 and 
CP67 protons, the STD-AF was saturated at high inhibitor 
concentrations and a good fit to the data was achieved to yield 
average KD,app values of 330 μM and 240 μM, respectively.  
However, even at high CP42 concentrations, the STD-AF did not 
show signs of saturation and suggests that the CP42 inhibitor is 
only weakly binding to CPG2 (low-mid mM range), if at all.  These 
results are in keeping with the results from the spectrophotometric 
assay with regards to the lack of CP42 binding and low-mid μM 
binding of both CP06 and CP67 (Fig 4), however the STD NMR 
analyses suggest that CP67 binds slightly more strongly than 
CP06, and also suggest a lower affinity for both inhibitors than 
was obtained from the IC50 values. This is in keeping with a recent 
report that STD-AF values can often underestimate KD [33]. For 
these reasons, STD-NMR data were used to reveal the binding 
epitopes within each inhibitor, while the absolute values of KD 
were interpreted with caution.    
 
 
 
 
 
 
 
Table 3. The KD,app values obtained from each individual curve fit (presented 
in Figure S6) of STD amplification factor vs. inhibitor concentration for each 
proton showing saturation transfer.  These values were used to calculate an 
average KD,app (± standard deviation) to estimate a global dissociation 
constant for each inhibitor. 
 
Inhibitor 
 
 
Proton number 
 
KD,app (mM) 
STD-NMR 
 
 
Average 
KD,app (mM) 
CP06 H1 0.34 0.33 ± 0.10 
 H2 0.45  
 H3[a] 1.33  
 H4 0.46  
 H5 0.23  
 H6 0.33  
 H7 0.20  
 H8 high  
 H9 high  
CP67 H1 0.33 0.24 ± 0.08 
 H2 0.25  
 H3 0.29  
 H4 0.25  
 H5 0.35  
 H6 0.33  
 H7 0.14  
 H8 0.17  
 H9 0.11  
 H9’ 0.08  
CP42 H7 24.67 n/a 
 H8 high  
 H9 2.28  
 
[a] This value was treated as an outlier, beyond 3  s.d. from the average, 
and was removed from the calculation of the reported average KD,app and 
standard deviation.  
n/a: not applicable 
Conclusions 
 In this work, we aimed to advance understanding of the 
molecular determinants of CPG2 activity by providing the first 
experimental data confirming residues, which drive catalytic 
activity and ligand recognition.  We carried out point mutation of 
residues predicted (by computational models) to lie in either the 
catalytic site or an adjacent putative binding pocket.  We 
confirmed that residues H112, E175 and D141 lie in the catalytic 
site and substitution of these residues with Ala results in 
abolishment of activity.  Two additional residues predicted to lie in 
the catalytic site and coordinate Zn, namely H385 and E200, 
appear to hold less critical roles in catalysis as their absence is 
tolerated by CPG2 with respect to both protein folding and activity.   
We also demonstrated the key role of residues K208, S210 and 
T357 (which are adjacent to the catalytic site and proposed to 
form the S1 pocket) in catalysis for the first time.  We propose that, 
similar to the S1’ pocket which has been shown to direct 
recognition of the glutamate portion of CPG2 substrates, the S1 
pocket directs recognition of the pteridine moiety in MTX and the 
naphthylamine moiety in our CPG2 inhibitors CP06 and CP67 
(and distinctly absent in CP42). This relationship between CPG2 
binding and structure can help to direct the design of future CPG2 
inhibitors with improved affinities.   
 While comparison of the IC50 values obtained here for CP06 
and CP67 to previously synthesized CPG2 inhibitors (e.g. the lead 
thiolate-containing inhibitor reported by Khan and co-workers[6] 
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with a Ki of 0.3 μM) suggests there is scope for improvement of 
binding and inhibition, it should be emphasized that strong binding 
was not our sole aim. The aim here was to create a new type of 
molecule capable of simultaneously inhibiting CPG2 whilst 
containing complex oligosaccharide moieties that could direct the 
enzyme for clearance via the kidneys or liver. CP67 fulfills this aim. 
STD-NMR epitope mapping confirmed that the glutamate and 
naphthylamine moieties in CP67 form a viable CPG2 binding-site 
with μM affinity which is entirely independent from, and does not 
interfere with, an attached galactosylated domain.  Likewise, none 
of the protons of the galactosylated domain in CP67 revealed 
proximity to CPG2 in STD-NMR experiments, suggesting this 
region is readily accessible for hepatocyte receptor binding.  
CP67 also opens up new chemical space in which to develop 
novel inhibitors as it contains a naphthylamine group, a functional 
group that has not been present in any previously reported CPG2 
substrate or inhibitor. 
Experimental Section 
Construction of CPG2 Mutants 
The CPG2-encoding gene in the absence of the signal peptide (CPG2 23-
415, residues 23-415) cloned in plasmid pET-151-D-Topo (Invitrogen, UK) 
previously developed in our laboratory (pET151-CPG223-415), was used 
as a template for PCR-based site-directed mutagenesis. The approach 
used was adapted from the QuikChange® Site-Directed Mutagenesis Kit 
from Invitrogen (Agilent Technologies, UK). The PCR reaction was 
performed using the high fidelity Phusion DNA (NEB, UK) polymerase to 
minimise the chances of introducing unwanted mutations in both the gene 
and the plasmid DNA backbone, and all mutated genes were verified via 
sequencing (GATC, Germany). 
Overexpression of Wild-type CPG223-415 
CPG223-415 and all mutated proteins were overexpressed with an N-
terminal His6 tag in the pET151 vector using BL21 (DE3) E.coli cells (New 
England Biolabs, UK). Protein expression was carried out by inoculating 1 
L of 2 × YT medium (supplemented with 100 μg L-1 ampicillin) with a 100 
mL overnight starter culture followed by shaking at 180 rpm and 37°C until 
an OD600 nm = 2 was reached. Induction of CPG2 expression was initiated 
with the addition of isopropyl -D-1-thiogalactopyranoside (IPTG) to a final 
concentration of 0.5 mM (unless otherwise stated), and cells were grown 
at 15°C yielding the highest expression levels. Cells were harvested by 
centrifugation at 4229 × g for 20 min. at 4°C.   
Purification of Recombinant Wild Type and Mutant CPG2 Proteins 
Cell pellets were resuspended in 10 ml Tris buffer (20 mM Tris, 137 mM 
NaCl, 1 mg mL-1 lysosome; 1mM 4-(2-aminoethyl) benzenesulfonyl 
fluoride hydrochloride; pH 7.3) and cells were lysed using a cell disruptor 
(30 kPSI). Once lysed, the insoluble fraction was pelleted by centrifugation 
(47,850 × g, 20 mins, 4°C). The Hisx6-tagged protein of interest was 
purified from the soluble fraction using Ni-NTA chromatography (Novagen). 
Imidazole was removed via buffer exchange using a PD-10 column. The 
N-terminal His-tag was removed by incubating CPG2 with TEV protease 
at 4°C for 48 hours. Cleaved protein was further purified using Ni-NTA 
resin (Novagen) followed by FPLC purification on a HiLoad 16/600 
Superdex 75 GL column (GE Healthcare UK Ltd. Buckinghamshire, UK) 
pre-equilibrated with 20 mM Tris HCl buffer (pH 8) containing 100 mM 
NaCl (Sigma, UK). FPLC was performed at 4°C and a flow rate of 0.5 mL 
min-1, and protein elution was monitored via absorbance at 280 nm.  
Sample Identification and Mass Determination by Mass Spectrometry 
Expression of the wild-type CPG223-415 and mutant proteins was confirmed 
using liquid chromatography electrospray ultra-high resolution quadrupole 
time-of-flight mass spectrometry (LC-ESI UHR QTOF). Samples 
containing 20 μM protein dissolved in 20 μM ammonium bicarbonate were 
diluted five-fold with 30% acetonitrile (ACN) with 0.1% formic acid (FA), 
and 40 μL aliquots of these were loaded onto a C4 column with 100% 
water and 0.1% FA as solvent A and 100% ACN with 0.1% FA as solvent 
B using a 3-step gradient (75% of solvent A for 16 min, 100% of solvent B 
for 5 min and 75% of solvent A for 11.5 min) and eluted directly into the 
MaXis II QTOF mass spectrometer (Bruker Daltonics). The resulting total 
ion count data (summed intensity across the entire range of masses being 
detected at every point in the analysis) was extracted and mass averaged 
in the region containing the proteins of interest, and deconvoluted using 
the Data Analysis Software (Bruker Daltonik GmbH; Bremen, Germany).  
Enzymatic Activity and Inhibition assay for CPG2 mutants 
The activity of CPG2 was estimated by measuring its ability to cleave 
methotrexate (MTX, which absorbs at 320 nm) into two species with 
altered absorbance properties, as described previously [22]. In the assay, 
50 μL of CPG2 solution (20 mM Tris buffer, 100 mM NaCl, pH 7.3) was 
added to a 1 mL quartz cuvette containing 900 μL of the assay buffer (0.1 
M Tris-HCl, 0.2 mM ZnCl2, pH 7.5) and 50 μL 0.6 mM methotrexate 
solution (0.1 M Tris-HCl, 0.2 mM ZnCl2, pH 7.5) pre-equilibrated to 37°C 
before addition of CPG2. When a potential inhibitor of CPG2 was tested, 
it was first diluted with the assay buffer.  In cases where the final 
concentration depended on solubility, the volume of assay buffer was 
adjusted to yield a final volume of 1 mL. Absorbance at 320 nm (A320¬) 
was measured using a Perkin Elmer Lambda 35 UV/VIS Spectrometer with 
Peltier temperature control unit for 1 minute, in time steps of 2 sec, and 
absorbance versus time (min) was plotted for each sample. The slope was 
calculated for the linear portion of the plot where the rate of the absorbance 
at 320 nm declined (typically between 0-1 min).  The activity was obtained 
in units per millilitre (U mL-1), where one unit is the amount of enzyme 
required to catalyse the hydrolysis of 1 μmol MTX per minute at 37°C. The 
measured absorbance of the assay buffer (blank) was subtracted from all 
measurements.  
Amplex® Red Assay for Evolution of Glutamic Acid 
Evolution of glutamic acid by CPG2 was measured using the Amplex® 
Red hydrogen peroxide/peroxidase assay kit (Thermo Fisher, UK). Briefly, 
if a CPG2 substrate (e.g. folic acid) was added to CPG2, glutamic acid will 
be released.  This glutamic acid was reacted with L-glutamate oxidase to 
produce -ketoglutarate and H2O2.  H2O2 was detected via a 1:1 reaction 
with the Amplex® Red reagent (10-acetyl-3,7-dihydroxyphenoxazine), in 
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combination with horseradish peroxidase (HRP), to produce the red-
fluorescent oxidation product, resorufin. Resorufin emission was 
monitored at 585 nm using a fluorescence spectrophotometer.  This 
approach was used to monitor glutamate evolution at 37°C in a black 96-
well plate for samples containing CPG2 (0.5 U/ml), folic acid (12.5 µM), 
and the Amplex® Red assay mixture according the manufacturer’s 
instructions. Folic acid was replaced by the CP06 inhibitor to demonstrate 
the lack of hydrolysis of the inhibitors. 
Circular Dichroism 
CD spectra of samples containing 0.1-0.2 mg mL-1 protein dissolved in 20 
mM Tris buffer (with 100 mM NaCl, 0.2 mM ZnCl2) were recorded in a 0.1 
mm path length cylindrical quartz cuvette (Starna, UK) using a J-815 
spectrophotometer (Jasco, UK). Spectra were recorded between 190 and 
260 nm, with a bandwidth of 2 mm, a scanning speed of 100 nm min-1 and 
8 scans. The CD spectrum of the buffer was recorded as a blank and was 
subtracted from each protein spectrum. The percentage of secondary 
structure content was estimated from CD spectra using DICHROWEB 
(UK) and reference dataset 7 [25, 34]. 
Thermal Denaturation 
 To record unfolding profiles of wild-type and mutant CPG2 proteins, 
samples were pre-warmed at 20°C and then slowly heated to 90°C at a 
rate of 1°C / min. Unfolding was monitored by CD on a Jasco J-1500 
spectrophotometer (Jasco, UK) equipped with a Peltier temperature 
control unit. Melting profiles at a constant wavelength of 220 nm, Θ220(T), 
were recorded during sample heating in 1 mm cells, with a bandwidth of 2 
mm and a scanning speed of 100 nm min-1. Heat-induced changes in 
solution turbidity indicating protein aggregation were also recorded by the 
dynode voltage V(T) that was recorded simultaneously with Θ220(T). 
CP06, CP67 and CP42 Inhibitor Production 
Peptides were produced using a Liberty Microwave Peptide Synthesiser 
(CEM Microwave Technology Ltd., UK) and a preloaded Fmoc-Glu(OtBu)-
TGA resin (Merck Chemicals). To prepare CP67 and CP42, custom made 
Fmoc-Ala-ANA-OH building blocks were used to avoid acylation of the 
naphthyl amino group. Reaction cycles were carried out on a 0.1 mM scale 
in DMF solvent using a 4-fold excess (with respect to resin loading) of 0.2 
M Fmoc and side chain-protected amino acid (where appropriate), 0.5 M 
HBTU and an 8-fold excess of 2 M DIPEA/NMP. The reaction time was 5 
minutes at a temperature of 75°C with double couplings used at each step. 
Deprotections were carried out in 20% Piperidine / DMF at a temperature 
of 80°C and reaction time of 2 minutes. Once complete, the resin was 
rinsed on a manifold with dichloromethane and then ethanol, and dried 
overnight in a vacuum desiccator. Cleavage and final deprotection of the 
peptide resin was carried out in 20 ml of 95% TFA / 2.5% triisopropylsilane 
/ 2.5% water for 90 minutes. The reaction liquors were dried by rotary 
evaporation and peptide precipitated in cold diethyl ether. After air drying, 
the residue was dissolved in 50 / 50 acetonitrile / water and freeze dried 
for 15 hours to yield an off white solid. To deacetylate the galactose sugars 
in CP67 and CP42, the peptide was dissolved in dry methanol and the pH 
adjusted dropwise to pH 10 with 1 M sodium methoxide in dry methanol. 
After 30 minutes, acetic acid was added to neutralise the reaction and the 
solvent was removed under a stream of nitrogen. In all cases, crude 
peptides were dissolved in 5% acetonitrile / water containing 0.1 % TFA 
and purified by HPLC on an Onyx C18 4.6×100 mm column (Phenomenex) 
using a buffer A (Water, 0.1% TFA) and buffer B (Acetonitrile 0.1% TFA) 
gradient of 5% − 100% B over 10 minutes. Pooled fractions were freeze 
dried to yield a white fluffy solid. Purified peptide was analysed by direct 
infusion on a ZMD electrospray mass spectrometer (Waters) to confirm 
expected mass. 
Inhibitor-Binding Studies by STD NMR  
 Wild-type CPG2 was dissolved in 20 mM Tris-d11 (pH 7.2) 
containing 0.1 M NaCl and 0.2 mM ZnCl2 to a final protein stock 
concentration of 40 μM. All inhibitors were prepared as concentrated (5 
mM) stock solutions. All NMR spectroscopy experiments were performed 
in 3 mm NMR tubes (Bruker, Germany) on a Bruker Avance 700 MHz 
instrument equipped with a 5 mm cryoprobe. NMR samples were prepared 
in 180 μL of 100% D2O buffer. A pseudo-2D version of the STD NMR pulse 
sequence was used for interleaved acquisition of off- and on-resonance 
spectra. The on-resonance frequency was set to either -301 Hz (-0.43 
ppm) or -700.24 Hz (-1 ppm) depending on the inhibitor, and the off-
resonance frequency was set to 30,000 Hz (42.8 ppm). Spectra were 
referenced to residual water. In all cases, control experiments containing 
no protein were performed to confirm the lack of direct saturation of 
inhibitor protons and select the appropriate on-resonance frequency. STD-
NMR spectra were acquired with a 2 s saturation time, 3 s relaxation delay, 
8 scans, and 4 dummy scans.  STD-NMR spectra were collected for 
samples containing 20 μM CPG2 and increasing concentrations of inhibitor 
ranging from 0 − 1.6 mM.  In the STD−NMR spectra, the STD intensity of 
a given inhibitor proton was considered to be directly proportional to the 
fraction of bound inhibitor, fB [33, 35] as shown in Equation 1:  
𝐟𝐁 =
[𝐏𝐈]
[𝐈]
=
(𝐈𝟎 − 𝐈𝐬𝐚𝐭)
𝐈𝟎
 
where [PI] is the concentration of the protein-inhibitor complex, [I] is the 
total concentration of the inhibitor, and I0 and Isat are the inhibitor proton 
peak intensities in the absence and presence of protein saturation, 
respectively. The STD amplification factor, STD−AF, is defined by Mayer 
and Meyer as the product of fB and the inhibitor excess (EI = [I]/ [P]) [31, 36]. 
Plotting STD−AF values at increasing values of [I] gives rise to a Michaelis-
Menten hyperbolic dose-response as described by Equation 2: 
𝐒𝐓𝐃 − 𝐀𝐅[𝐈] =
𝐒𝐓𝐃 − 𝐀𝐅𝐦𝐚𝐱 [𝐈]
[𝐈] + 𝐊𝐃
 
where STD−AFmax is a dimensionless scaling factor representing the 
maximum STD amplification factor for the monitored signals. Mathematical 
fitting yields both parameters KD and STD−AFmax. For each inhibitor 
concentration, STD−AF[I] build-up curves were recorded. To determine KD 
values following the standard procedure, the STD−AF values (at a given 
saturation time) of an inhibitor proton were plotted as a function of the 
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concentration of inhibitor, and the resulting data were fitted to Equation 2 
to yield the apparent KD, KD,app. 
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